ATE326223T1 - Methode zur behandlung der hyperaktiven blase - Google Patents

Methode zur behandlung der hyperaktiven blase

Info

Publication number
ATE326223T1
ATE326223T1 AT01941430T AT01941430T ATE326223T1 AT E326223 T1 ATE326223 T1 AT E326223T1 AT 01941430 T AT01941430 T AT 01941430T AT 01941430 T AT01941430 T AT 01941430T AT E326223 T1 ATE326223 T1 AT E326223T1
Authority
AT
Austria
Prior art keywords
hyperactive bladder
compound
methods
treating hyperactive
treating
Prior art date
Application number
AT01941430T
Other languages
English (en)
Inventor
Russell A Bialecki
William Rumsey
Keith Russell
Peter Bernstein
David Aharony
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE326223T1 publication Critical patent/ATE326223T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01941430T 2000-06-22 2001-06-20 Methode zur behandlung der hyperaktiven blase ATE326223T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0015246.2A GB0015246D0 (en) 2000-06-22 2000-06-22 Method for the treatment of urinary incontinence

Publications (1)

Publication Number Publication Date
ATE326223T1 true ATE326223T1 (de) 2006-06-15

Family

ID=9894138

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01941430T ATE326223T1 (de) 2000-06-22 2001-06-20 Methode zur behandlung der hyperaktiven blase

Country Status (9)

Country Link
US (1) US20030139433A1 (de)
EP (1) EP1307202B1 (de)
JP (1) JP2003535901A (de)
AT (1) ATE326223T1 (de)
AU (1) AU2001274786A1 (de)
DE (1) DE60119742T2 (de)
ES (1) ES2262654T3 (de)
GB (1) GB0015246D0 (de)
WO (1) WO2001097811A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001295359A1 (en) * 2000-10-30 2002-05-15 University Of Zurich GnRH analogues for treatment of urinary incontinence
SE0103668D0 (sv) * 2001-11-02 2001-11-02 Astrazeneca Ab Method for the treatment of overactive blader
SE0103795D0 (sv) * 2001-11-02 2001-11-02 Astrazeneca Ab Compounds and method for the treatment of överactive bladder
US20040248989A1 (en) 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms
EP2158910A1 (de) * 2003-10-27 2010-03-03 Novartis Ag Verwendung von Neurokinin-Antagonisten bei der Behandlung von Harnstoffinkontinenz
WO2006121389A1 (en) * 2005-05-10 2006-11-16 Astrazeneca Ab Use of a neurokinin-2 receptor antagonist for treating or preventing detrusor overactivity
AU2018282104A1 (en) * 2017-06-06 2019-12-12 Urovant Sciences Gmbh Use of vibegron to treat overactive bladder
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9317104D0 (en) * 1993-08-17 1993-09-29 Zeneca Ltd Therapeutic heterocycles
GB9322643D0 (en) * 1993-11-03 1993-12-22 Zeneca Ltd Lactam derivatives
US6008223A (en) * 1994-10-27 1999-12-28 Zeneca Limited Therapeutic compounds
GB9505084D0 (en) * 1995-03-14 1995-05-03 Pfizer Ltd Benzamide derivative
US6365602B1 (en) * 1998-07-10 2002-04-02 Astra Zeneca Ab N-substituted naphthalene carboxamides as neurokinin-receptor antagonists
GB9922519D0 (en) * 1998-10-07 1999-11-24 Zeneca Ltd Compounds
GB9924141D0 (en) * 1998-10-30 1999-12-15 Zeneca Ltd Treatment of gastric asthma
GB9826941D0 (en) * 1998-12-09 1999-02-03 Zeneca Pharmaceuticals Compounds

Also Published As

Publication number Publication date
GB0015246D0 (en) 2000-08-16
AU2001274786A1 (en) 2002-01-02
EP1307202B1 (de) 2006-05-17
US20030139433A1 (en) 2003-07-24
JP2003535901A (ja) 2003-12-02
DE60119742T2 (de) 2007-05-31
WO2001097811A1 (en) 2001-12-27
EP1307202A1 (de) 2003-05-07
ES2262654T3 (es) 2006-12-01
DE60119742D1 (de) 2006-06-22

Similar Documents

Publication Publication Date Title
ATE536353T1 (de) 2-(4-amino-1,2,5-oxadiazol-4-yl)-imidazol- verbindungen als protein kinase inhibitoren
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
DE60312017D1 (de) Sulfonderivate zur hemmung von gamma-secretase
GB0225474D0 (en) Therapeutic agents
ATE396731T1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
DE60332433D1 (de) Azolylaminoazine als proteinkinasehemmer
DE60332604D1 (de) Azolylaminoazine als proteinkinasehemmer
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
DE60134874D1 (de) Benzodiazepin-derivate als gamma-secretase inhibitoren
ATE316785T1 (de) Jak-3 hemmer zur behandlung von allergischen störungen
DE60231804D1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen
ATE320803T1 (de) Verfahren zur behandlung von alzheimerschen krankheit
ATE224884T1 (de) Muscarin-antagonisten
ATE422357T1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
DE60127537D1 (de) VERWENDUNG VON 2-(4-ETHOXY-PHENYL)-3-(4-METHANESULFONYL-PHENYL)-PYRAZOLOÄ1,5-bÜPYRIDAZINE ZUR BEHANDLUNG VON NICHTULZERATIVER DYSPEPSIE
MXPA05007771A (es) Procedimientos de tratamiento del dolor articular o para mejorar el sueno usando un agonista/antagonista de estrogeno.
ATE326223T1 (de) Methode zur behandlung der hyperaktiven blase
DE60108626D1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b] pyridinen als cyclin-abhängige kinase-hemmer
ATE369348T1 (de) Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
MXPA02000330A (es) Pirrolidinas y piperidinas neurotroficas y composiciones y metodos relacionados.
ATE390134T1 (de) (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4- fluorophenyl)ethyl)-4-piperidinemethanol oder prodrug davon zur behandlung von demenzsymptomen oder kognitiven störungen
BR0213832A (pt) Composto, método para tratamento ou prevenção de bexiga superativa ou incontinência urinária em um indivìduo, composição farmacêutica, e, uso de (s)-n-[2-(3,4-diclorofenil)-4-[4-(2-oxo-piperidin-1-il)piperi dino]butil]-n-metil-2-fluorobenzamida ou um sal farmaceuticamente aceitável da mesma
DE60117541D1 (de) Candesartan zur Behandlung von Migräne
DE60130677D1 (de) 1-(2-m-methansulfonamidophenylethyl)-4-(m-trifluoromethylphenyl)piperazine und ihre akzeptablen pharmazeutischen salze und solvate und ihre verwendung zur behandlung von inkontinenz

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties